Tesamorelin Dosage
Tesamorelin Dosage: What Research Reports
The short answer
Tesamorelin dosage in published research and on the FDA label is 2 mg by subcutaneous injection once daily (Falutz et al., 2007; FDA Egrifta label). In the pivotal phase 3 trial of 412 adults, that dose reduced visceral adipose tissue by about 15 percent over 26 weeks versus placebo (Falutz et al., 2007). Tesamorelin is a synthetic growth-hormone-releasing hormone (GHRH) analog sold as Egrifta, and its only FDA-approved use is reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy (FDA Egrifta label). This page reports what studies and the label state. It is not a dose for you; a qualified clinician sets any personal dose.
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What tesamorelin dosage did research report?
The studied tesamorelin dosage was 2 mg given by subcutaneous injection once daily, both in the pivotal trial and on the original FDA Egrifta label (Falutz et al., 2007; FDA Egrifta label).
The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.
| Source | Population studied | Dose reported | Route and frequency | Reported outcome |
|---|---|---|---|---|
| Falutz et al., 2007 (NEJM) | Adults with HIV-associated lipodystrophy (n=412) | 2 mg | Subcutaneous, once daily | About 15 percent reduction in visceral adipose tissue over 26 weeks versus placebo |
| FDA Egrifta label | Adults with HIV-associated lipodystrophy | 2 mg | Subcutaneous, once daily | Approved for reducing excess visceral abdominal fat |
These figures describe what researchers used and what regulators approved. They are not instructions, and they do not fit every person. Any personal dose is a clinical decision.
Note on formulations: the figures above reflect the original Egrifta trial and label. A later single-vial formulation (Egrifta SV) carries its own separately approved dosing on its own label. Always read the label that matches the exact product.
What is tesamorelin?
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) that signals the pituitary gland to release the body's own growth hormone. It reached the market under the brand name Egrifta and is the only GHRH analog with an FDA-approved indication: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy (FDA Egrifta label). The compound was tested in a randomized, placebo-controlled phase 3 trial reported by Falutz et al. in the New England Journal of Medicine in 2007 (Falutz et al., 2007; doi:10.1056/NEJMoa072375).
How does tesamorelin work in the body?
Tesamorelin binds GHRH receptors on the pituitary and prompts a natural, pulse-like release of growth hormone, which then raises IGF-1 (Falutz et al., 2007). Because it acts upstream, it works through the body's own feedback loops rather than replacing growth hormone directly. That distinction is why researchers group it with GHRH analogs rather than with growth hormone itself.
What did the tesamorelin trial measure?
The main measure was change in visceral adipose tissue (VAT) on CT imaging, and the trial reported about a 15 percent reduction versus placebo across 26 weeks in 412 adults (Falutz et al., 2007). Researchers also tracked IGF-1, which rose in line with the drug's mechanism. The endpoint was a fat-distribution marker, not a general body-weight claim.
How does tesamorelin compare with other growth hormone secretagogues?
Tesamorelin is one of several compounds that act on the growth hormone axis, but they differ in molecule, mechanism, and evidence.
| Compound | Class | What research reports | Source |
|---|---|---|---|
| Tesamorelin | GHRH analog | About 15 percent visceral fat reduction in HIV-associated lipodystrophy | Falutz et al., 2007 |
| CJC-1295 | GHRH analog | Sustained rise in growth hormone and IGF-1 after a single dose | Teichman et al., 2006 |
| Ipamorelin | Ghrelin-type GH secretagogue | Selective growth hormone release with minimal cortisol effect | Raun et al., 1998 |
| MK-677 (ibutamoren) | Oral GH secretagogue | Higher fasting glucose, lower insulin sensitivity at 25 mg/day | Nass et al., 2008 |
This grid compares mechanism and evidence only. It is not a dosing guide, and these compounds are not interchangeable.
What safety signals did research note?
Because tesamorelin raises growth hormone and IGF-1, studies watched blood glucose, injection-site reactions, and fluid-related effects (Falutz et al., 2007). Growth-hormone-axis compounds can influence glucose control: in a separate secretagogue, MK-677, researchers reported higher fasting glucose and lower insulin sensitivity at 25 mg per day (Nass et al., 2008). The FDA label carries contraindications and monitoring guidance, and any safety question belongs with a qualified clinician.
Why doesn't this page give me a personal dose?
Because a safe dose depends on your health history, current medications, lab values, and goals, which only a qualified clinician can weigh. PL reports what peer-reviewed trials and regulatory labels state so you can ask sharper questions. It does not prescribe, and the compounds it lists are sold for research use. For background on this class of molecules, see what are peptides.
Keep reading
Related research and verification
Tesamorelin Dosage: FAQ
References
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375. PMID 18057338.
- U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection), for subcutaneous use. Full Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID 9849822.
- Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, et al. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial. Ann Intern Med. 2008;149(9):601-611. doi:10.7326/0003-4819-149-9-200811040-00003.
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.